Company news

Regenxbio Inc. news in 2019

Regenxbio Inc.'s news releases, calls and decks from 2019, newest first.

View company

REGENXBIO Reports Third Quarter 2019 Financial and Operating Results and Recent Operational Highlights

November 4, 2019

REGENXBIO To Host Conference Call on November 5 to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights

October 28, 2019

REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress

October 16, 2019

REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

October 10, 2019

REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314

September 3, 2019

REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD

August 6, 2019

REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV® AAV9 Vector

July 30, 2019

REGENXBIO Expands Pipeline Using NAV Vectors to Deliver Therapeutic Antibodies for the Treatment of Hereditary Angioedema and Neurodegenerative Diseases

July 23, 2019

REGENXBIO Announces Completion of Dosing for Phase I/IIa Clinical Trial of RGX-314 in Wet AMD

May 29, 2019

REGENXBIO Announces First FDA Approval of a Gene Therapy Based on Its Proprietary NAV® Technology Platform

May 23, 2019

REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer

April 16, 2019

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting

April 14, 2019

Decks in 2019